ubiquitin ligase inhibitors (CellCentric)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameubiquitin ligase inhibitors (CellCentric)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUbiquitin-protein ligases inhibitorsAndrogen Receptor degraders
TargetsUbiquitin-protein ligasesAndrogen Receptor
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCellcentric Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellcentric Ltd
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A